Literature DB >> 2328212

A prognostic score in histological node negative breast cancer.

B Chevallier1, V Mosseri, J P Dauce, P Bastit, J P Julien, B Asselain.   

Abstract

Between October 1977 and December 1983, 379 consecutive patients have been treated for unilateral, non-metastatic breast cancer, either with conservative (n = 205) or radical surgery (n = 174), with axillary dissection in all the cases. None of them had histologically proved lymph node involvement. Oestrogen receptor (ER) and progesterone receptor (PR) levels were measured on each tumour. Levels greater than 5 fmol mg-1 cytosolic protein were considered as positive for both ER and PR. At 5 years, overall survival (OS) and disease-free survival (DFS) are respectively 88% and 78%. Unifactorial analysis using Kaplan and Meier estimates and the log rank test revealed that OS was significantly related to age (P less than 0.05), tumour size (P less than 0.001), histological grading (SBR) (P less than 0.01), ER (P less than 0.001) and PR (P less than 0.001). DFS was significantly related to the same factors. Menopausal status, number of breast tumour foci and previous familial history of breast cancer were not significant. Multifactorial analysis revealed that DFS was significantly related to age (bad prognosis (b.p.) less than or equal to 37 years old), tumour size and histological grading (b.p. SBR = 3), and that OS was significantly related to tumour size and PR (b.p. PR less than or equal to 5 fmol mg-1 protein). A prognostic score has been constructed for both DFS and OS. These scores divide our patients into three significantly different (P less than 0.0001) groups with good, intermediate and bad prognosis.

Entities:  

Mesh:

Year:  1990        PMID: 2328212      PMCID: PMC1971289          DOI: 10.1038/bjc.1990.96

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Natural history of lymph-node-negative breast cancer.

Authors:  W A Albano; C D Hanf; C H Organ
Journal:  Surgery       Date:  1979-10       Impact factor: 3.982

2.  Cancer of the breast: size of neoplasm and prognosis.

Authors:  B Fisher; N H Slack; I D Bross
Journal:  Cancer       Date:  1969-11       Impact factor: 6.860

3.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

4.  Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma.

Authors:  S K Moot; G N Peters; J H Cheek
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

5.  Management and survival of female breast cancer: results of a national survey by the American College of Surgeons.

Authors:  T Nemoto; J Vana; R N Bedwani; H W Baker; F H McGregor; G P Murphy
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

6.  Pathologic identification of poor prognosis stage I (T1N0M0) cancer of the breast.

Authors:  T F Nealon; A Nkongho; C Grossi; J Gillooley
Journal:  Ann Surg       Date:  1979-08       Impact factor: 12.969

7.  Tumour DNA ploidy as an independent prognostic factor in breast cancer.

Authors:  O P Kallioniemi; G Blanco; M Alavaikko; T Hietanen; J Mattila; K Lauslahti; T Koivula
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

8.  A prognostic index in primary breast cancer.

Authors:  J L Haybittle; R W Blamey; C W Elston; J Johnson; P J Doyle; F C Campbell; R I Nicholson; K Griffiths
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

9.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

10.  Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance.

Authors:  M Trojani; I de Mascarel; F Bonichon; J M Coindre; G Delsol
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

View more
  8 in total

1.  The Nottingham Prognostic Index in primary breast cancer.

Authors:  M H Galea; R W Blamey; C E Elston; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Steroid receptors in early breast cancer.

Authors:  P S Stonelake; P R Baker; P G Baker; J M Morrison; D Spooner
Journal:  BMJ       Date:  1992-07-04

Review 3.  General surgery.

Authors:  I Taylor
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

4.  Prognostic factors in breast cancer: the value of the Nottingham Prognostic Index for patients treated in a single institution.

Authors:  Homa Okugawa; Daigo Yamamoto; Yoshiko Uemura; Noriko Sakaida; Masanori Yamada; Kanji Tanaka; Yasuo Kamiyama
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

5.  Role of age as a prognostic factor in breast cancer.

Authors:  A Tsuchiya; R Abe; M Kanno; T Ohtake; T Fukushima; T Nomizu; I Kimijima
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

6.  Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system.

Authors:  Min Yi; Elizabeth A Mittendorf; Janice N Cormier; Thomas A Buchholz; Karl Bilimoria; Aysegul A Sahin; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo; Sheng Luo; Aman U Buzdar; Jaime R Crow; Henry M Kuerer; Kelly K Hunt
Journal:  J Clin Oncol       Date:  2011-11-14       Impact factor: 44.544

7.  Monoclonal antibody BrE-3 participation in a multivariate prognostic model for infiltrating ductal carcinoma of the breast.

Authors:  C M Chan; F S Baratta; L Ozzello; R L Ceriani
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients.

Authors:  Ines Zemni; Montassar Ghalleb; Ichraf Jbir; Maher Slimane; Jamel Ben Hassouna; Tarek Ben Dhieb; Hatem Bouzaiene; Khaled Rahal
Journal:  World J Surg Oncol       Date:  2017-11-23       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.